Evidence map›Paper›PMID 42416481›Full record

ArticleNano today2022

Nano-vectors for CRISPR/Cas9-Mediated Genome Editing.

Peng Yang, Athena Yue-Tung Lee, Jingjing Xue, Shih-Jie Chou, Calvin Lee, Patrick Tseng, Tiffany X Zhang, Yazhen Zhu, Junseok Lee, Shih-Hwa Chiou and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nano today, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Peng YangDepartment of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging (CIMI), California NanoSystems Institute (CNSI), University of California, Los Angeles, Los Angeles, California 90095, United States.
Athena Yue-Tung LeeDepartment of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging (CIMI), California NanoSystems Institute (CNSI), University of California, Los Angeles, Los Angeles, California 90095, United States.
Jingjing XueDepartment of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging (CIMI), California NanoSystems Institute (CNSI), University of California, Los Angeles, Los Angeles, California 90095, United States.
Shih-Jie ChouDepartment of Medical Research, and Stem Cell Center, Division of Basic Research, Taipei Veterans General Hospital, Institute of Pharmacology, College of Medicine, National Yang Ming Chiao Tung University, No. 155, Sec. 2, Linong Street 112, Taipei, Taiwan.
Calvin LeeDepartment of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging (CIMI), California NanoSystems Institute (CNSI), University of California, Los Angeles, Los Angeles, California 90095, United States.
Patrick TsengDepartment of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging (CIMI), California NanoSystems Institute (CNSI), University of California, Los Angeles, Los Angeles, California 90095, United States.
Tiffany X ZhangDepartment of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging (CIMI), California NanoSystems Institute (CNSI), University of California, Los Angeles, Los Angeles, California 90095, United States.
Yazhen ZhuDepartment of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging (CIMI), California NanoSystems Institute (CNSI), University of California, Los Angeles, Los Angeles, California 90095, United States.
Junseok LeeDepartment of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging (CIMI), California NanoSystems Institute (CNSI), University of California, Los Angeles, Los Angeles, California 90095, United States.
Shih-Hwa ChiouDepartment of Medical Research, and Stem Cell Center, Division of Basic Research, Taipei Veterans General Hospital, Institute of Pharmacology, College of Medicine, National Yang Ming Chiao Tung University, No. 155, Sec. 2, Linong Street 112, Taipei, Taiwan.
Hsian-Rong TsengDepartment of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging (CIMI), California NanoSystems Institute (CNSI), University of California, Los Angeles, Los Angeles, California 90095, United States.

Funding

Supramolecular Nanoparticle-Based PET Probes for Pretargeted Tumor ImagingR21EB016270 · NIBIB · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TSENG, HSIAN-RONG · 2013 to 2014
$400k
NIBIB NIH HHS R21 EB016270
6 · The paper itself

Abstract

The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (CRISPR/Cas9) genome editing system has revolutionized the field of genome editing for therapeutic applications for genetic diseases and cancers, the development of disease models, identification of targets for drug development. However, safe and efficient delivery of the CRISPR/Cas9 genome editing system in vivo remains a significant challenge. Compared to viral vectors, non-viral nano-vectors have the following advantages: cost-effective, scale-up production, ease of chemical modification, large packaging capacity, lower immunogenicity, better protection of CRISPR/Cas9 genome edition system from degradation in vivo. This comprehensive Review article highlights the recent advances in delivering the three categories of CRISPR/Cas9 genome editing cargoes (i.e., Cas9 DNA plasmid, Cas9 mRNA, and Cas9 ribonucleoprotein) by using three types of nano-vectors: lipid-based, polymer-based, and polymer inorganic nano-vectors to treat cancers and genetic diseases via two major gene-editing pathways: non-homologous end joining pathway and homology-directed repair pathway. This article also notes the therapeutic applications for treating cancers and genetic diseases, provides insights into the challenges of nano-vectors for the delivery of the CRISPR/Cas9 genome editing system and proposes promising strategies in future development, especially in the final clinical translation.

Indexed as

CRISPR/Cas9genome editingnanoparticlesnano-vectorsnonviral delivery

Identifiers

PMID42416481
PMCPMC13341159

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.